Efficacy and tolerability of antiepileptic drugs in an Omani epileptic population

Clinical Neurology and Neurosurgery

Volumn 108, Issue 6, 2006, Pages 532-538

  Hanssens, Yolande ^a   Asmi, Abdullah Al ^b   Busaidi, Intisar Al ^b   Deleu, Dirk ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

Antiepileptic drugs; Efficacy; Epilepsy; Oman; Seizures; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; EVALUATION; EYE TOXICITY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAND MAL EPILEPSY; HOSPITAL PATIENT; HUMAN; IDIOPATHIC DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; MONOTHERAPY; NEUROLOGY; NEUROTOXICITY; SIDE EFFECT; THERAPY EFFECT; UNIVERSITY HOSPITAL; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; OMAN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33746911214     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2005.08.007     Document Type: Article

References (35)

1. Kotsopoulos I.A., van Merode T., Kessels F.G., de Krom M.C., and Knottnerus J.A. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 43 (2002) 1402-1409
2. Sander J.W., and Shorvon S.D. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 61 (1996) 433-443
3. Brodie M.J., and Kwan P. Staged approach to epilepsy management. Neurology 58 Suppl. 5 (2002) 2-8
4. Brodie M.J., and Dichter M.A. Antiepileptic drugs. N Engl J Med 334 (1996) 168-175
5. Beghi E., Di Mascio R., and Tognoni G. Drug treatment of epilepsy: outlines, criticism and perspectives. Drugs 31 (1986) 249-265
6. http://www.nationbynation.com [accessed 24 July 2004].
7. Hanssens Y., Deleu D., and Taqi A. Etiologic and demographic characteristics of poisoning: a prospective hospital-based study in Oman. J Toxicol Clin Toxicol 39 (2001) 371-380
8. Hanssens Y., Deleu D., Al Balushi K., Al Hashar A., and Al-Zakwani I. Drug utilization pattern of anti-epileptic drugs: a pharmacoepidemiologic study in Oman. J Clin Pharm Ther 27 (2002) 357-364
9. Al-Zakwani I., Hanssens Y., Deleu D., Cohen A., McGhan W., Al-Balushi K., et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure 12 (2003) 555-560
10. Deleu D., Aarons L., and Ahmed I.A. Population pharmacokinetics of free-carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol 57 (2001) 243-248
11. Deleu D., Aarons L., and Ahmed I.A. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Arch Med Res 36 (2005) 49-53 Erratum: Arch Med Res 2005;36:186
12. Commission on Classification Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22 (1981) 489-501
13. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30 (1989) 389-399
14. Aziz H., Guvener A., Akhtar S.W., and Hasan K.Z. Comparative epidemiology of epilepsy in Pakistan and Turkey: population-based studies using identical protocols. Epilepsia 38 (1997) 716-722
15. Abduljabbar M., Ogunniyi A., Daif A.K., Al-Tahan A., Al-Bunyan M., and Al-Rajeh S. Epilepsy classification and factors associated with control in Saudi adult patients. Seizure 7 (1998) 501-504
16. Chadwick D.W. Diagnosis of epilepsy. Lancet 336 (1990) 291-295
17. Kalviainen R. Monotherapy trial design: conversion versus de novo. Epilepsy Res 45 (2001) 75-78
18. Chadwick D. Monotherapy clinical trials of new antiepileptic drugs: design, indications, and controversies. Epilepsia 38 Suppl. 9 (1997) 16-20
19. Mattson R.H., Cramer J.A., Collins J.F., Smith D.B., Delgado-Escueta A.V., Browne T.R., et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313 (1985) 145-151
20. Sander J.W. Some aspects of prognosis in the epilepsies: a review. Epilepsia 34 (1993) 1007-1016
21. Mattson R.H., Cramer J.A., and Collins J.F. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Neurology 47 (1996) 68-76
22. Dean J.C., and Penry J.K. Discontinuation of antiepileptic drugs. In: Levy R.H., Dreifuss F.E., Mattson R.H., Meldrum B.S., and Penry JK. (Eds). Antiepileptic drugs. 3rd ed. (1999), Raven Press, New York 133-142
23. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in remission. Lancet 337 (1991) 1175-1180
24. Bourgeois B., Beaumanoir A., Blajev B., de la Cruz N., Despland P.A., Egli M., et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 28 Suppl. 2 (1987) S8-S11
25. Hassan M.N., Laljee H.C., and Parsonage M.J. Sodium valproate in the treatment of resistant epilepsy. Acta Neurol Scand 54 (1976) 209-218
26. Andersen E.B., Philbert A., and Klee J.G. Carbamazepine monotherapy in epileptic out-patients. Acta Neurol Scand Suppl 94 (1983) 29-34
27. Curry W.J., and Kulling D.L. Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin. Am Fam Physician 57 (1998) 513-520
28. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment. Epilepsia 29 (1988) 787-793
29. Richens A., Davidson D.L., Cartlidge N.E., and Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry 57 (1994) 682-687
30. Biton V., Mirza W., Montouris G., Vuong A., Hammer A.E., and Barrett P.S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56 (2001) 172-177
31. Luef G., Abraham I., Hoppichler F., Trinka E., Unterberger I., Bauer G., et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 51 (2002) 1274-1278
32. Corman C.L., Leung N.M., and Guberman A.H. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 24 (1997) 240-244
33. Ebert U., and Löscher W. Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: influence of genetic factors. Epilepsy Res 33 (1999) 217-226
34. Chkhenkeli S.A., Šramka M., Lortkipanidze G.S., Rakviashvili T.N., Bregvadze ESh, Magalashvili G.E., et al. Electrophysiological effects and clinical results of direct brain stimulation for intractable epilepsy. Clin Neurol Neurosurg 106 (2004) 318-329
35. Tanganelli P., Ferrero S., Colotto P., and Regesta G. Vagus nerve stimulation for treatment of medically intractable seizures Evaluation of long-term outcome. Clin Neurol Neurosurg 105 (2002) 9-13